LivaNova PLC

NASDAQ:LIVN

Medical - Devices

Healthcare
$94.54 +0.96%

+$0.76 today

Market cap
$5.21B
Beta
0.88
P/E (TTM)
40.5
EPS (TTM)
$1.96
52W Low $41.02High $80.96

Volume 1.32M

Average 0.79M

LIVN Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

LivaNova PLCNASDAQ: LIVN

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures grows, but more slowly than its trailing trend

Q3 FY2026 capital expenditures of $30.8M (cash outflow) rose 34.6% year over year, behind the +83.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at +45.2% a year.

Context

  • Capital expenditures amounted to 5.8% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Capital expenditures grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +34.6% toward the trailing-twelve-month pace of +83.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$30.8M-2.4% QoQ
Last fiscal yearDec 2025
-$81.1M+72.2% YoY
LTMSep 2026
-$108.84M+83.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.6%——
1 year+72.2%——
3-year CAGR+45.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(81.1M) USD
Year-over-year change
-72.2%

Capital Expenditures vs competitors

How LIVN compares with its peers on the latest reported figures

  • LIVN's LTM Sep 2026 capital expenditures of $108.84M is the 5th largest of the 10 companies compared; the peer median is $39.98M.
  • Its year-over-year change of +83.8% is the 2nd highest of 10, against a peer median of +5.4%.
  • Capital expenditures amounts to 7.2% of revenue for LIVN, versus a peer median of 4.3%.
LIVN Competitors Peer median
Capital Expenditures for LIVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$1.9B +3.3%+9.3%5.1%
BSXBoston Scientific CorporationLTM Jun 2026$904M -7.2%+12.7%4.3%
EWEdwards Lifesciences CorporationLTM Jun 2026$286.7M +53.3%-0.6%4.4%
RMDResMed Inc.LTM Jun 2026$267.46M +188.0%+5.3%4.7%
LIVNLivaNova PLCLTM Sep 2026$108.84M +83.8%+45.2%7.2%
INSPInspire Medical Systems, Inc.LTM Jun 2026$39.98M +23.3%+61.8%4.4%
HAEHaemonetics CorporationLTM Jun 2026$36.93M -1.2%-33.2%2.7%
STIMNeuronetics, Inc.LTM Mar 2026$779K -40.5%-37.4%0.5%
CVRXCVRx, Inc.LTM Mar 2026$588K +5.4%-5.4%1.0%
NPCENeuroPace, Inc.LTM Mar 2026$412K +72.4%-18.0%0.4%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding LIVN) $39.98M+5.4%-0.6%4.3%

Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(135.82M)(86.2M)17.55M63.23M(242.5M)
Depreciation & Amortization67.99M57.8M60.86M51.14M42M
Deferred Income Tax2.85M1.4M(114.43M)6.8M500K
Stock-Based Compensation40.56M44.81M36.35M33.93M36.3M
Change in Working Capital29.22M(31.7M)(34.62M)1.31M369.97M
Accounts Receivables(15.75M)(4.8M)(28.86M)11.1M(10.7M)
Inventory4.48M(25.7M)(28.48M)(6.8M)(5.3M)
Accounts Payables12.99M(3.5M)19.19M(14.5M)(13.4M)
Other Working Capital27.49M2.3M3.53M11.51M399.41M
Other Non-Cash Items97.74M83.8M109.21M26.63M48.03M
Operating Cash Flow102.54M69.9M74.91M183.04M254.3M
Capital Expenditures(25.48M)(26.5M)(34.98M)(47.11M)(81.1M)
Acquisitions (Net)41.25M(8.9M)000
Purchases of Investments(3.65M)(3M)(6.5M)(1.14M)(5.7M)
Sales of Investments23.06M88K006.5M
Other Investing Activities1.73M(88K)1.15M89K7.4M
Investing Cash Flow36.9M(38.4M)(40.33M)(48.16M)(72.9M)
Debt Repayment(487.85M)284.01M26.4M87.97M(280.93M)
Common Stock Issued309.62M00035K
Common Stock Repurchased(12.94M)(8.7M)(7.5M)(8.44M)(4.43M)
Dividends Paid00000
Other Financing Activities9.69M4.8M2.59M(60.98M)(378K)
Financing Cash Flow(181.48M)280.1M21.48M18.55M(285.7M)
Effect of Forex Changes(2.81M)(4M)6.19M(7.75M)16.2M
Net Change in Cash(44.84M)307.6M62.25M145.68M(88M)
Free Cash Flow77.07M43.4M39.93M135.93M173.2M

LivaNova PLC

NASDAQ:LIVN

Intrinsic Alpha fair value

Locked

Current Price

$94.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.